期刊文献+

原发灶不明癌24例临床分析 被引量:5

下载PDF
导出
摘要 目的分析原发灶不明癌的临床特点,探讨其治疗及预后。方法回顾性分析了2003年8月至2007年3月期间收治的24例原发灶不明癌患者,分析病理类型、治疗方式、全身化疗周期数、受累器官数目等与生存期的关系。结果病理类型、治疗方式、化疗周期数、累及器官数目等均对生存期有一定影响,但运用Cox比例风险回归模型对预后因素进行分析,结果显示只有治疗方式(P=0.011)和化疗周期数(P=0.008)是影响预后的独立因素。结论采用紫杉类加铂类化疗及全身热疗的患者和化疗周期数达3个或以上的患者生存期相对较长。
作者 陈华 黄建瑾
出处 《中国实用医药》 2007年第36期39-41,共3页 China Practical Medicine
  • 相关文献

参考文献8

  • 1[1]Abbruzzese JL,Abbruzzese MC,Lenzi R,et al.Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.J Clin Oncol,1995,13(8):2094 -2103.
  • 2[2]Pavlidis N,Fizazi K.Cancer of unknown primary (CUP).Crit Rev Oncol Hematol,2005,54(3):243-250.
  • 3[3]Shaw PHS,Adams R,Jordan C,et al.A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.Clin Oncol,2007,19 (1):87-95.
  • 4[4]Varadhachary GR,Abbruzzese JL,Lenzi R.Diagnostic strategies for unknown primary cancer.Cancer,2004,100(9):1776-1785.
  • 5[5]Van de Wouw AJ,Janssen-Heijnen ML,Coebergh JW,et al.Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands,1984-1992.Eur J Cancer,2002,38 (3):409-413.
  • 6[6]Park YH,Ryoo BY,Choi SJ,et al.A Phase Ⅱ Study of Paclitaxel plus Cisplatin Chemotherapy in an Unfavourable Group of Patients with Cancer of Unknown Primary Site.Jpn J Clin Oncol,2004,34(11):681-685.
  • 7[7]Arends J.Effects of a combined thermochemotherapy on markers of opoptosis,differentiation and adhesion in the human mammary carcinoma MX21:A light microscopic and immunohistochemical study.Anat Anz,2000,182(4):339-347.
  • 8[8]Stein U,Urchott K,Walther W,et al.Hyperthermia induced nuclear translocation of transcription factor YB 21 leads to enhanced expression of multidrug resistance related ABC transporters.J Biol Chem,2001,276 (30):28562-28569.

同被引文献26

  • 1吴毅.原发灶不明颈部转移性鳞癌的诊治[J].中华肿瘤防治杂志,2006,13(12):881-883. 被引量:9
  • 2Pavlidis N,Fizazi K.Cancer of unknown primary(CUP)[J].Crit Rev Oncol Hematol,2005,54(3):243-250.
  • 3Shaw PHS,Adams R,Jordan C,et al.A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network[J].Clin Oncol,2007,19(1):87-95.
  • 4Park YH,Ryoo BY,Choi SJ,et al.A phaseⅡstudy of paclitaxal plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site[J].Jpn J Clin Oncol,2004,34(11):681-685.
  • 5Thom I,Rogers C,Andritzky B,et al.Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years[J].Onkologie,2009,32 (12):741-746.
  • 6Mevio E, Gorini E, Sbrocca M, et al. The role of positron e- mission tomography (PET) in the management of cervical lymph nodes metastases from an unknown primary turnout. Acta Otorhinolaryngol Ital, 2004, 24(6): 342-347.
  • 7Pavlidis N,Fizazi K. Cancer of unknown primary(CUP). Crit Rev Oncol Heraatol, 2005,54 (3) : 243-250.
  • 8Van de Wouw AJ ,Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours: incidence and population-based survival of 1285 patients in Southeast Neth- erlands,1984-1992. Eur J Cancer,2002,38(3) :409-413.
  • 9Shaw PHS,Adams R,Jordan C,et al. A clinical review of the investigation and management of carcinoma of unknown pri- mary in asingle cancer network. Clin Oncol, 2007,19 ( 1 ) : 87- 95.
  • 10Vant-Veer LJ,Weigelt B. Road map to metastasis. Nat Med, 2003,9 (8) : 999-1000.

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部